Phase III, A placebo controlled, randomised, three period cross-over trial to investigate the protective effect in a histamine challenge test of a new formulation compared to a reference formulation in paediatric patients aged 4 – 12 years with asthma.

• The population selected for this trial were paediatric subjects with proven asthma.
• 39 subjects were screened
• 33 patients were randomised to treatment
• and 27 patients completed the trial.

Trial period: 2005